Kamada (NASDAQ:KMDA) Stock Breaks Below Two Hundred Day Moving Average - Here's What Happened

Key Points

• Kamada shares fell below their 200-day moving average, trading as low as $7.68 and last changing hands at $7.77, below the $7.82 average.
• Analysts remain bullish, with a consensus “Buy” rating and an average price target of $13.50; UBS Group and William Blair each set $15 targets.
• Kamada’s latest quarterly results beat expectations, with EPS of $0.16 versus $0.11 estimated and revenue of $54.92 million versus $50.84 million, although its annual dividend was reduced to $0.17 from $0.25 per share.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) shares passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $7.82 and traded as low as $7.68. Kamada shares last traded at $7.77, with a volume of 88,202 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on KMDA shares. UBS Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Weiss Ratings raised Kamada from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, October 9th. Benchmark reiterated a "buy" rating on shares of Kamada in a research report on Tuesday, July 21st. William Blair set a $15.00 price target on shares of Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Kamada from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $13.50.

Kamada Trading Up 0.5%

The company has a 50 day simple moving average of $8.20 and a 200 day simple moving average of $7.82. The stock has a market capitalization of $446.85 million, a PE ratio of 20.45, a P/E/G ratio of 0.65 and a beta of 0.89.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The firm had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%. On average, equities research analysts predict that Kamada Ltd. will post 0.48 EPS for the current year.

Kamada Cuts Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were given a dividend of $0.17 per share. This represents a yield of 206.0%. This is a negative change from Kamada's previous annual dividend of $0.25. The ex-dividend date of this dividend was Thursday, August 27th. Kamada's dividend payout ratio is presently 34.21%.

Hedge Funds Weigh In On Kamada

An institutional investor recently raised its position in Kamada stock. Aristides Capital LLC grew its stake in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,491 shares of the biotechnology company's stock after purchasing an additional 1,476 shares during the quarter. Aristides Capital LLC owned approximately 0.06% of Kamada worth $288,000 as of its most recent SEC filing. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada's portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.